Comparative Pharmacology
Head-to-head clinical analysis: PROKLAR versus ZITHROMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROKLAR versus ZITHROMAX.
PROKLAR vs ZITHROMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PROKLAR (clarithromycin) is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide chain elongation.
Azithromycin is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by preventing translocation of peptides. It also has immunomodulatory and anti-inflammatory effects.
500 mg orally every 12 hours for 7-14 days.
500 mg orally once daily for 3 days, or 2 g orally as a single dose for certain infections.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours (prolonged to 6-8 hours in hepatic impairment); context: requires q8-12h dosing in normal renal function
Terminal elimination half-life of approximately 68 hours (range 35-96 hours), allowing once-weekly dosing for some indications.
Renal: 20-30% unchanged; fecal: 15-30%; biliary: 5-10%; total renal excretion of metabolites: ~70%
Primarily eliminated via biliary/fecal route (∼50-60% as unchanged drug); renal excretion accounts for ∼12% of the dose; minimal metabolism.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic